5439042025-04-012025-06-305439042025-06-305439042025-04-012025-06-30in-capmkt:OtherExpenses1Member5439042025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15439042025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25439042025-04-012025-06-30AuditorDomain15439042025-04-012025-06-30AuditorDomain25439042025-06-30Statement15439042025-04-012025-06-30Statement15439042025-06-30StatementDynamic1I1Statement15439042025-06-30StatementDynamic1I2Statement15439042025-06-30StatementDynamic1I3Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares543904MANKINDNOTLISTEDINE634S01028MANKIND PHARMA LIMITEDMain BoardEquity2025-04-012026-03-312025-07-312025-07-14INRCroresQuarterlyFirst quarterSingle segmentPharmaceuticals2025-07-3114:30:002025-07-3115:50:00Declaration of unmodified opiniontrue1falseThere is no default on loans and Debt securities hence No disclosure is required to be made in this report for the quarter ended on June 30, 2025.2025-04-012025-06-30UnauditedStandalone25413600000642200000260558000002247600000414470000030410000058487000001467000000969300000613780000021119200000493660000004936600000921400000-11240000080900000004127600000000041276000001060000041382000004127000001109.9900109.990.00460.00760.0393Due to limitation of characters in xbrl utility, we are facing constraints to disclose all notes to accounts. Kindly refer PDF version of financials results uploaded on the Stock Exchanges website: www.bseindia.com and www.nseindia.com and also on the Company’s website: www.mankindpharma.com.Other expenses6137800000Remeasurement losses of the defined benefit plan-60000000Change in the fair value of equity investments at FVTOCI58100000-1900000-12500000010600000UnauditedtrueS.R. Batliboi & Co. LLPtrue2027-07-31Bhagi Bhardwaj Gaur & Cotrue2028-05-31QIP2024-12-20300000000002025-06-30trueCARE RATINGS LIMITEDfalseNo CommentsNo CommentsHitesh Kumar JainCompany Secretary and Compliance OfficerNew Delhi2025-07-31Repayment of Commercial Paper Series I None290000000000290003000000General Corporate PurposesNone55000000005500000000Issue expensesNone450000000044970000001. The issue-related expenses were initially paid by the subsidiary, Bharat Serums and Vaccines Limited (BSV), in December 2024 and January 2025 from its own funds. <br></br> In May 2025, the company reimbursed BSV from its internal accruals and subsequently reimbursed itself from the QIP proceeds. <br></br> 2. The total value of the QIP-related invoices paid to the subsidiary was approximately Rs 2.72 crore, of which around Rs 2.43 crore was funded from the remaining QIP proceeds.